BRAF mutations are observed in most melanocytic nevi (70–80%), metastatic melanomas (40–50%), and vertical growth phase melanomas (40–50%) [37–39], and might be an acquired event in early invasive melanoma that induces clonal expansion and tumor progression [36]. Here, BRAF is linked to neoplasm.